COVID-19 in Cyanotic Congenital Heart Disease

dc.contributor.authorAmmar, Lama A.
dc.contributor.authorNassar, Joseph E.
dc.contributor.authorBitar, Fadi Fouad
dc.contributor.authorArabi, Mariam Toufic
dc.contributor.departmentPediatrics and Adolescent Medicine
dc.contributor.facultyFaculty of Medicine (FM)
dc.contributor.institutionAmerican University of Beirut
dc.date.accessioned2025-01-24T12:11:21Z
dc.date.available2025-01-24T12:11:21Z
dc.date.issued2023
dc.description.abstractCongenital heart disease (CHD) is the most prevalent congenital defect in newborn infants. Due to the various types of heart abnormalities, CHD can have a wide range of symptoms. Cardiac lesions comprise a range of different types and accordingly varying severities. It is highly helpful to classify CHD into cyanotic and acyanotic heart diseases. In this review, we are investigating the course of Coronavirus disease 2019 (COVID-19) in cyanotic CHD patients. The infection may directly or indirectly affect the heart by affecting the respiratory system and other organs. The effect on the heart that is pressure- or volume-overloaded in the context of CHD is theoretically more severe. Patients with CHD are at a higher risk of mortality from COVID-19 infection or suffering worse complications. While the anatomic complexity of CHD does not seem to predict the severity of infection, patients with worse physiological stages are more susceptible such as cyanosis and pulmonary hypertension. Patients with CHD exhibit continuous hypoxemia and have lower oxygen saturations because of a right-to-left shunt. Such individuals run the danger of rapidly deteriorating in the event of respiratory tract infections with inadequate oxygenation. Additionally, these patients have a higher risk of paradoxical embolism. Hence, critical care should be given to cyanotic heart disease patients with COVID-19 in comparison to acyanotic patients and this is through proper management, close observation, and adequate medical therapy. © 2023 Lama A Ammar et al.
dc.identifier.doihttps://doi.org/10.1155/2023/5561159
dc.identifier.eid2-s2.0-85157967264
dc.identifier.urihttp://hdl.handle.net/10938/32548
dc.language.isoen
dc.publisherHindawi Limited
dc.relation.ispartofCanadian Journal of Infectious Diseases and Medical Microbiology
dc.sourceScopus
dc.subjectAortic coarctation
dc.subjectAortic regurgitation
dc.subjectAortic valve stenosis
dc.subjectArticle
dc.subjectChemiluminescence immunoassay
dc.subjectClustered regularly interspaced short palindromic repeat
dc.subjectCongenital heart disease
dc.subjectCoronavirus disease 2019
dc.subjectCyanosis
dc.subjectCyanotic heart disease
dc.subjectDisease severity
dc.subjectDroplet digital polymerase chain reaction
dc.subjectEnzyme linked immunosorbent assay
dc.subjectFallot tetralogy
dc.subjectGreat vessels transposition
dc.subjectHeart atrium septum defect
dc.subjectHeart right left shunt
dc.subjectHeart ventricle septum defect
dc.subjectHigh throughput sequencing
dc.subjectHuman
dc.subjectHypoxemia
dc.subjectLateral flow immunochromatography
dc.subjectLung vein drainage anomaly
dc.subjectMortality
dc.subjectOxygen saturation
dc.subjectOxygenation
dc.subjectParadoxical embolism
dc.subjectPatent ductus arteriosus
dc.subjectPulmonary hypertension
dc.subjectPulmonary valve stenosis
dc.subjectReal time polymerase chain reaction
dc.subjectRespiratory tract infection
dc.subjectReverse transcription loop mediated isothermal amplification
dc.subjectSevere acute respiratory syndrome coronavirus 2
dc.subjectSupravalvular aortic stenosis
dc.subjectTricuspid valve atresia
dc.subjectVaccination
dc.titleCOVID-19 in Cyanotic Congenital Heart Disease
dc.typeArticle

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
2023-1191.pdf
Size:
750.14 KB
Format:
Adobe Portable Document Format